Vukusich 2010.

Study characteristics
Methods	Study design: parallel RCT Study duration: not reported Follow‐up duration: 2 years
Participants	Setting: single centre Country: Chile Relevant health status: CKD‐5D on HD Number: treatment group (33); control group (33) Mean age ± SD (years): treatment group (60.1 ± 5.2); control group (55.6 ± 3.6) Sex (M/F): treatment group (14/9); control group (20/10) Exclusion criteria: pregnancy or potassium level > 5.5 mEq/L
Interventions	Treatment group Spironolactone 50 mg/HD for 104 weeks Control group Placebo for 104 weeks
Outcomes	Death (any cause) Serum potassium
Identification	Authors name: Antonio Vukusich Institution: Faculty of Medicine, Universidad Los Andes, Santiago Email: emarusic@uandes.cl Address: S. Carlos Apoquindo2200, Santiago, Chile
Notes	Funding source: This research was supported by grants FONDECYT 1040338 and Fondo Ayuda Investigaction Universidad Los Andes MED 002/06. Complete follow‐up: treatment group (30/33, 90.9%); control group (23/33, 69.7%)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only states the study was randomised, does not ensure how sequence generation was done
Allocation concealment (selection bias)	Unclear risk	Only states the study was randomised, does not ensure how allocation concealment was done
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "placebo‐controlled randomised clinical trial"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "placebo‐controlled randomised clinical trial"
Incomplete outcome data (attrition bias) All outcomes	High risk	Imbalance in numbers for missing data across intervention groups
Selective reporting (reporting bias)	Low risk	All prespecified outcomes have been reported in study protocol in materials and methods section
Other bias	Low risk	This research was supported by grants FONDECYT 1040338 and Fondo Ayuda Investigacion Universidad Los Andes MED 002/06